+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Gliosarcoma - Pipeline Review, H2 2019

  • ID: 4901283
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 344 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Agenus Inc
  • Astellas Pharma Inc
  • Bristol-Myers Squibb Co
  • EpicentRx Inc
  • Ipsen SA
  • NewLink Genetics Corp
  • MORE
Gliosarcoma - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Gliosarcoma - Pipeline Review, H2 2019, provides an overview of the Gliosarcoma (Oncology) pipeline landscape.

Gliosarcoma is a type of brain tumor that originates from glial cells. The tumor grows rapidly and symptom will vary depending on the exact location and size of the tumor. Most likely they may be headache, vomiting, cognitive problems, and drowsiness. Treatment of brain tumors depends upon the type and staging of the tumor, its size and position in the brain, as well as the age and other health problems of patient.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Gliosarcoma - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Gliosarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gliosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gliosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 17, 14 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Phase 0 stages comprises 1, 1 and 2 molecules, respectively.

Gliosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Gliosarcoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Gliosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Gliosarcoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Gliosarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Gliosarcoma (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Gliosarcoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Gliosarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Agenus Inc
  • Astellas Pharma Inc
  • Bristol-Myers Squibb Co
  • EpicentRx Inc
  • Ipsen SA
  • NewLink Genetics Corp
  • MORE
Introduction
Report Coverage
Gliosarcoma - Overview
Gliosarcoma - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Gliosarcoma - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Gliosarcoma - Companies Involved in Therapeutics Development
Adastra Pharmaceuticals Inc
Agenus Inc
Apexigen Inc
Arog Pharmaceuticals Inc
Astellas Pharma Inc
Bayer AG
Berg LLC
Bristol-Myers Squibb Co
CDG Therapeutics Inc
DNAtrix Inc
EpicentRx Inc
ERC Belgium SA
Gilead Sciences Inc
Ipsen SA
Merck & Co Inc
Millennium Pharmaceuticals Inc
Mustang Bio Inc
NewLink Genetics Corp
Northwest Biotherapeutics Inc
Novartis AG
Oncologie Inc
TheraBiologics Inc
Transtarget Inc
Gliosarcoma - Drug Profiles
Gliosarcoma - Dormant Projects
Gliosarcoma - Discontinued Products
Gliosarcoma - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Gliosarcoma, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Gliosarcoma - Pipeline by Adastra Pharmaceuticals Inc, H2 2019
Gliosarcoma - Pipeline by Agenus Inc, H2 2019
Gliosarcoma - Pipeline by Apexigen Inc, H2 2019
Gliosarcoma - Pipeline by Arog Pharmaceuticals Inc, H2 2019
Gliosarcoma - Pipeline by Astellas Pharma Inc, H2 2019
Gliosarcoma - Pipeline by Bayer AG, H2 2019
Gliosarcoma - Pipeline by Berg LLC, H2 2019
Gliosarcoma - Pipeline by Bristol-Myers Squibb Co, H2 2019
Gliosarcoma - Pipeline by CDG Therapeutics Inc, H2 2019
Gliosarcoma - Pipeline by DNAtrix Inc, H2 2019
Gliosarcoma - Pipeline by EpicentRx Inc, H2 2019
Gliosarcoma - Pipeline by ERC Belgium SA, H2 2019
Gliosarcoma - Pipeline by Gilead Sciences Inc, H2 2019
Gliosarcoma - Pipeline by Ipsen SA, H2 2019
Gliosarcoma - Pipeline by Merck & Co Inc, H2 2019
Gliosarcoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2019
Gliosarcoma - Pipeline by Mustang Bio Inc, H2 2019
Gliosarcoma - Pipeline by NewLink Genetics Corp, H2 2019
Gliosarcoma - Pipeline by Northwest Biotherapeutics Inc, H2 2019
Gliosarcoma - Pipeline by Novartis AG, H2 2019
Gliosarcoma - Pipeline by Oncologie Inc, H2 2019
Gliosarcoma - Pipeline by TheraBiologics Inc, H2 2019
Gliosarcoma - Pipeline by Transtarget Inc, H2 2019
Gliosarcoma - Dormant Projects, H2 2019
Gliosarcoma - Discontinued Products, H2 2019

List of Figures
Number of Products under Development for Gliosarcoma, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Adastra Pharmaceuticals Inc
  • Agenus Inc
  • Apexigen Inc
  • Arog Pharmaceuticals Inc
  • Astellas Pharma Inc
  • Bayer AG
  • Berg LLC
  • Bristol-Myers Squibb Co
  • CDG Therapeutics Inc
  • DNAtrix Inc
  • EpicentRx Inc
  • ERC Belgium SA
  • Gilead Sciences Inc
  • Ipsen SA
  • Merck & Co Inc
  • Millennium Pharmaceuticals Inc
  • Mustang Bio Inc
  • NewLink Genetics Corp
  • Northwest Biotherapeutics Inc
  • Novartis AG
  • Oncologie Inc
  • TheraBiologics Inc
  • Transtarget Inc
Note: Product cover images may vary from those shown
Adroll
adroll